Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Generate Biomedicines, Inc. (GENB : NSDQ)

• Company Description    Generate Biomedicines Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Generate Biomedicines Inc. is based in SOMERVILLE, Mass. Number of Employees: 312

• Price / Volume Information    Yesterday's Closing Price: $16.39 Daily Weekly Monthly 20 Day Moving Average: 1,397,537 shares Shares Outstanding: 128.35 (millions) Market Capitalization: $2,103.70 (millions) Beta: 52 Week High: $22.67 52 Week Low: $11.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.35% 11.84% 12 Week 20.69% 18.12% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101 SOUTH STREET SUITE 900 - SOMERVILLE,MA 02143 USA ph: 888-469-0055 fax: - investors@generatebiomedicines.com http://www.generatebiomedicines.com

• General Corporate Information    Officers Michael Nally - Chief Executive Officer Noubar B. Afeyan - Chairperson Jason Silvers - President and Chief Financial Officer Frances Arnold - Director Stephane Bancel - Director Peer Information Generate Biomedicines, Inc. (CORR.) Generate Biomedicines, Inc. (RSPI) Generate Biomedicines, Inc. (CGXP) Generate Biomedicines, Inc. (BGEN) Generate Biomedicines, Inc. (GTBP) Generate Biomedicines, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 370920100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 128.35 Most Recent Split Date: (:1) Beta: Market Capitalization: $2,103.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.61 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 51.40% Sales Growth vs. Year Ago Period: -37.67% vs. Previous Quarter: -12.60% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - - 12/31/25 - - Current Ratio 06/30/26 - 8.30 03/31/26 - 9.17 12/31/25 - 2.85 Quick Ratio 06/30/26 - 8.30 03/31/26 - 9.17 12/31/25 - 2.85 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - -698.59 Book Value 06/30/26 - 3.55 03/31/26 - 4.02 12/31/25 - - Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - - Debt-to-Capital 06/30/26 - 0.30 03/31/26 - 0.43 12/31/25 - -

Powered by Zacks Investment Research ©